Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

215,521-215,550 of 319,975

filter-aware
26
Uses a nested circle diagram to show market segmentation and penetration.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
27
Uses a chevron-style arrow to indicate progression from current state to future state.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
28
The slide tracks the shift in revenue mix towards higher-margin channels.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
29
Includes non-GAAP financial measures and constant currency growth rates.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
30
Sonos | Results Presentation Deck | 33 slidesSonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
31
Financial data in thousands, unaudited. Includes detailed footnotes explaining legal/transaction costs and restructuring/abandonment costs.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
32
Includes footnotes explaining legal/transaction costs and the 2023 restructuring plan.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
33
Note: $ in thousands, unaudited.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
01
Slide 1
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
02
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
03
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
04
The slide uses a three-column layout to categorize strategic priorities.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
05
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
06
Slide serves as a product introduction/cover slide for a corporate presentation.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
07
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
08
The slide shows two line charts tracking market share growth in different care settings.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
09
The slide highlights consistent growth in both metrics, with Q/Q growth percentages annotated above each bar.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
10
Uses a Venn diagram to illustrate the patient segments (Dexterity Challenges, Cognitive Impairment, Suboptimal PIFR) that define the addressable population.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
11
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
12
The slide outlines a clinical trial methodology using a timeline-based study design.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
The slide illustrates how findings from one study (PIFR-1) informed the design of a subsequent study (PIFR-2) by narrowing the patient population to GOLD 3/4, resulting in statistically significant improvement.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
15
The slide outlines a clinical trial design using a randomized withdrawal methodology.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
16
The slide uses a combination of a market sizing summary at the top and a competitive landscape table at the bottom.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
17
The slide uses a classic 'problem vs. solution' or 'market gap vs. strategic imperative' structure.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
18
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Satisfaction1 hit
19
Includes GAAP and non-GAAP financial measures.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
20
The slide provides a standard financial reconciliation table.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
21
The slide includes specific footnotes regarding non-GAAP adjustments and share buyback activity.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
22
The chart shows a significant reduction in operating expenses from 2020 to 2023.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit